

# EVALUATION OF STINGLESS BEE HONEY FROM Heterotrigona itama COCKERELL AS ANTI-OBESITY AGENT IN HIGH FAT DIET-INDUCED OBESITY SPRAGUE-DAWLEY RAT MODEL

AHMAD ZULKIFLI BIN MOHD RAFIE

FBSB 2017 48



# EVALUATION OF STINGLESS BEE HONEY FROM *Heterotrigona itama* COCKERELL AS ANTI-OBESITY AGENT IN HIGH FAT DIET-INDUCED OBESITY SPRAGUE-DAWLEY RAT MODEL



AHMAD ZULKIFLI BIN MOHD RAFIE


Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfillment of the Requirements for the Degree of Master of Science

December 2017

# COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Master of Science

# EVALUATION OF STINGLESS BEE HONEY FROM *Heterotrigona itama* COCKERELL AS ANTI-OBESITY AGENT IN HIGH FAT DIET-INDUCED OBESITY SPRAGUE-DAWLEY RAT MODEL

By

#### AHMAD ZULKIFLI BIN MOHD RAFIE


December 2017

# Chairman: MariatulqabtiahBte Abdul Razak, PhDFaculty: Biotechnology and Biomolecular Sciences

Heterotrigona itama is a common stingless bee species of Malaysia. However, studies on the health benefits of its honey are relatively limited compared to other stingless bee species of the world. In this study, the anti-obesity properties of stingless bee honey from *H. itama* were evaluated based on the weight changes, biochemistry parameters and morphological structures in diet-induced obese rat model. 56 male Sprague Dawley (SD) rats were induced with formulated high fat diet (HFD) to become obese, indicated by the value of  $0.68 \text{ g/cm}^2$ , for 6 weeks. Then, treatment phase was carried out for the next 6 weeks. At the end of the experiment, rats were euthanized and their blood and organs (liver, aorta and adipose tissue) were sampled. Results showed significant reduction in percentages of body weight gain and adiposity index in groups treated with all the three dosages of stingless bee honey with percentages of body weight gain of  $12.0 \pm 3.1$ ,  $-2.3 \pm 2.9$ and  $11.1 \pm 4.6$  and adiposity index of  $5.6 \pm 0.3$ ,  $4.6 \pm 0.5$  and  $6.8 \pm 0.8$ , for 1000 mg/kg, 750 mg/kg and 500 mg/kg supplementations, respectively, compared to the control obese group with excess of percentage of body weight gain of  $33.7 \pm 2.8$  and adiposity index of  $10.1 \pm 0.5$ . For the biochemistry analysis based on blood serum, levels of liver enzymes (ALT, AST and alkaline phosphatase) were significantly lower in all treated groups with 1000 mg/kg showing  $51.0 \pm 4.9$ ,  $154.5 \pm 19.0$  and  $104.2 \pm 25.5$ , 750 mg/kg showing 56.3  $\pm$  5.6, 183.3  $\pm$  18.0 and 122.0  $\pm$  9.3, and 500 mg/kg showing  $64.8 \pm 8.6$ ,  $206.3 \pm 18.9$  and  $140.5 \pm 9.0$ , respectively. Lipid profiles of (triglycerides and LDL-cholesterol) were also significantly lower in all treated groups with 1000 mg/kg showing  $0.73 \pm 0.08$  and  $0.17 \pm 0.061$ , 750 mg/kg showing  $0.83 \pm 0.08$  and  $0.12 \pm 0.031$ , and 500 mg/kg showing  $0.78 \pm 0.08$  and  $0.17 \pm 0.021$ , respectively, compared to control obese group which showed  $1.33 \pm 0.22$  and  $0.70 \pm$ 0.132, respectively. Level of HDL-cholesterol in treated groups was significantly higher with 1000 mg/kg showing  $1.33 \pm 0.10$ , 750 mg/kg showing  $1.35 \pm 0.09$ , and



500 mg/kg showing  $1.30 \pm 0.09$ , compared to control obese group which showed  $0.93 \pm 0.11$ . Based on morphological structures, adipocyte size was smaller and hepatocytes were less ruptured in treated groups compared to untreated groups at  $40 \times$  magnification. Histology results of aorta in treated groups directly mimic to the normal-like structure, compared to untreated groups. As a conclusion, the intervention study suggested that administration of stingless bee honey was successful to reduce the complication risks related to obesity such as liver disease. Our study also suggests that stingless bee honey possesses hepatoprotective action that could be used to control obesity by regulating lipid metabolism.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

# PENILAIAN MADU KELULUT DARIPADA SPESIS Heterotrigona itama SEBAGAI AGEN ANTI-OBESITI TERHADAP MODEL TIKUS SPRAGUE-DAWLEY OBES YANG DIARUH DENGAN MAKANAN TINGGI LEMAK

Oleh

#### AHMAD ZULKIFLI BIN MOHD RAFIE

Disember 2017

# Pengerusi: Mariatulqabtiah Bte Abdul Razak, PhDFakulti: Bioteknologi dan Sains Biomolekul

Heterotrigona itama merupakan salah satu spesis lebah kelulut di Malaysia. Setakat ini, penyelidikan tentang kebaikan madu itu terhadap kesihatan masih lagi kurang jika dibandingkan dengan spesis lebah kelulut yang lain di dunia. Ciri-ciri antiobesiti madu kelulut spesis H. itama terhadap model tikus yang obesiti dinilai berdasarkan perubahan berat, parameter-parameter biokimia dan struktur morfologi. Sebanyak 56 tikus jantan jenis 'Sprague Dawley' diberi makan setiap hari dengan makanan diet berlemak tinggi yang dihasilkan sendiri sehingga tikus-tikus itu mencapai tahap obesiti iaitu pada kadar melebihi 0.68g/cm<sup>2</sup> sehingga enam minggu. Selepas itu, fasa rawatan dijalankan selama enam minggu. Pada akhir minggu keenam, haiwan dikorbankan dan darah serta organ (hati, aorta, dan tisu adipos) diambil. Keputusan menunjukkan terdapat pengurangan dalam peratusan pertambahan berat dan indeks adipositi dalam kumpulan yang menerima rawatan tiga dos madu kelulut dengan peratusan pertambahan berat adalah  $12.0 \pm 3.1$ ,  $-2.3 \pm$ 2.9 dan 11.1  $\pm$  4.6 dan indeks adiposity adalah 5.6  $\pm$  0.3, 4.6  $\pm$  0.5 dan 6.8  $\pm$  0.8 untuk 1000 mg/kg, 750 mg/kg dan 500 mg/kg suplemen, masing-masing, dibandingkan dengan kumpulan kawalan obes yang mempunyai lebih peratusan pertambahan berat sebanyak  $33.7 \pm 2.8$  dan indeks adiposity sebanyak  $10.1 \pm 0.5$ . Bagi analisis biokimia serum darah, kadar bacaan enzim hati (ALT, AST dan phosphatase alkali) adalah ketara lebih rendah dalam semua kumpulan yang menerima rawatan dengan 1000 mg/kg menunjukkan 51.0  $\pm$  4.9, 154.5  $\pm$  19.0 dan  $104.2 \pm 25.5$ , 750 mg/kg menunjukkan 56.3  $\pm$  5.6, 183.3  $\pm$  18.0 dan 122.0  $\pm$  9.3, dan 500 mg/kg menunjukkan 64.8  $\pm$  8.6, 206.3  $\pm$  18.9 dan 140.5  $\pm$  9.0, masing-masing. Profil lipid (trigliserida dan kolesterol lipoprotein ketumpatan rendah) adalah ketara lebih rendah di semua kumpulan tikus yang menerima rawatan dengan 1000 mg/kg menunjukkan 073  $\pm$  0.08 dan 0.17  $\pm$  0.061, 750 mg/kg menunjukkan 0.83  $\pm$  0.08 dan  $0.12 \pm 0.031$ , dan 500 mg/kg menunjukkan  $0.78 \pm 0.08$  dan  $0.17 \pm 0.021$ , masingmasing, berbanding kumpulan kawalan obes yang menunjukkan  $1.33 \pm 0.22$  dan  $0.70 \pm 0.132$ , masing-masing. Kadar bacaan kolesterol lipoprotein ketumpatan tinggi di kumpulan tikus yang menerima rawatan adalah ketara lebih tinggi dengan 1000 mg/kg menunjukkan  $1.33 \pm 0.10$ , 750 mg/kg menunjukkan  $1.35 \pm 0.09$ , dan 500 mg/kg menunjukkan  $1.30 \pm 0.09$ , masing-masing, berbanding kumpulan kawalan obes yang menunjukkan  $0.93 \pm 0.11$ . Struktur morfologi menunjukkan saiz adipos lebih kecil dan struktur hepatosit kurang rosak di kumpulan tikus yang menerima rawatan madu berbanding yang tidak mendapat rawatan madu di bawah pembesaran  $40 \times$ . Keputusan histologi aorta menunjukkan struktur yang sama di antara kumpulan tikus yang mendapat rawatan madu dan kumpulan tikus normal, berbanding kumpulan tikus yang tidak menerima rawatan madu. Kesimpulannya, rawatan menggunakan madu kelulut berjaya menurunkan risiko komplikasi obesiti seperti penyakit hati. Hasil penyiasatan ini mencdangkann madu kelulut mempunyai tindakan protektif-hepa yang mampu mengawal obesiti dengan kawalan metabolisma lipid.

#### ACKNOWLEDGEMENTS

In the name of Allah, the most gracious and the most merciful, all praise to Allah for giving me strength to finish up my research project at Institute of Bioscience, University Putra Malaysia, Serdang Selangor. This success is due to His will and His Mercy.

Firstly, I would like to express my gratitude to my supervisor Dr. Mariatulqabtiah Abdul Razak for the continuous support in my project, for her patient, motivation and immense knowledge throughout the entire period of my research project. Her guidance helped me a lot in all time of project and writing up of this thesis. Besides, I would like to thanks to my co-supervisors, Dr. Wan Amir Nizam Wan Ahmad from USM Kubang Kerian for their expert contribution and thanks also for all opinions and spending their time to look up on my thesis.

I also would like to take this opportunity to express my gratitude to my laboratory colleague for their kindness in helping me throughout the project. Special thanks also to all staffs of Animal Research & Service Centre (ARASC), Scanning Electron Microscope (SEM), Central Research Laboratory (CRL) and Unit Pengurusan Makmal Sains (UPMS), Universiti Sains Malaysia Kubang Kerian for their help throughout my research project.

Last but not least, I would like to thank to my family members especially my beloved parents Mohd Rafie Bin Abdullah Kamari & Siti Norlijah Binti Jamari and also En Ahmad Damanhury Bin Ibrahim and Pn Juliana Abdullah for their endless support, love and always energize me throughout my project. Not forgotten, to my dear friends, thanks for all opinion, advice, encouragement and vast memory that has been created along this journey.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

#### Mariatulqabtiah Bte Abdul Razak, PhD

Associate Professor Faculty of Biotechnology and Biomolecular Sciences Universiti Putra Malaysia (Chairman)

#### Amir Syahir Bin Amir Hamzah, PhD

Associate Professor Faculty of Biotechnology and Biomolecular Sciences Universiti Putra Malaysia (Member)

## Wan Amir Nizam Bin Wan Ahmad, PhD

Associate Professor School of Health Sciences Universiti Sains Malaysia (Member)

## Mohd Zulkifli Bin Mustafa, PhD

Associate Professor School of Medical Science Universiti Sains Malaysia (Member)

## **ROBIAH BINTI YUNUS, PhD**

Professor and Dean School of Graduate Studies Universiti Putra Malaysia

Date:

# **Declaration by graduate student**

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software


Signature:	Date:

Name and Matric No.: Ahmad Zulkifli Bin Mohd Rafie, GS42748

# **Declaration by Members of Supervisory Committee**

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.



# TABLE OF CONTENTS

ABSTRACT

AB	STRAK			iii
AC	CKNOWLI	EDGEM	IENTS	v
AP	PROVAL			vi
DE	ECLARAT	ION		viii
	ST OF TA			xiii
	ST OF FIG			xiv
	ST OF AB		ATIONS	xix
CH	IAPTER			
1	INTR	ODUC	FION	1
	1.1	Obesit		1
	1.2		ess Bee Honey ( <i>Heterotrigona itama species</i> )	1
	1.3	Object		2
			General Objective	
		1.3.2		2 2
	1.4	Hypotl		2
				•
2			RE REVIEW	3
	2.1	Obesit		3 3
			Oxidative stress, Obesity and Antioxidants	
		2.1.2	Current Status of Anti-Obesity Medications	4
			2.1.2.1 Orlistat	5
		212	2.1.2.2 Mechanism of Action of Orlistat	7
		2.1.3	Fat Degradation	8
			2.1.3.1 Fat Rich Diet as Indicator for Development of	10
			Obesity 21.2.2 Obesity and New Alashelia Fatty, Liver	10
			2.1.3.2 Obesity and Non-Alcoholic Fatty Liver	11
	2.2	Hanari	Disease (NAFLD)	11
	2.2	•	as a Natural Source for Treatment of Various Diseases	12 12
		2.2.1 2.2.2	Natural Compound from the Honey and Its Potential	12
		2.2.2	Antioxidant Properties and Phenolic Acid Composition	14
		222	of Malaysian Honeys	14
	22	2.2.3	Toxicology of Honey	14 15
	2.3	0	ess Bee Honey Stingless Des Honey in Therepoutie Application	
		2.3.1 2.3.2	Stingless Bee Honey in Therapeutic Application Potential of Honey in Promoting Lower Weight Gain	16 16
		2.3.2	Folential of Honey in Fromoting Lower weight Gam	10
3	MAT	ERIAL	S AND METHODS	18
	3.1	Materi	als	18
		3.1.1	Natural Source Materials	18
		3.1.2	Chemical and Drugs	18

i

	3.1.3	Treatment/ Drug Preparation	19
		3.1.3.1 High Fat Diet (HFD) Preparation (32%	
		cholesterol) for Induction Phase	19
		3.1.3.2 Treatment Preparation for Intervention Phase	20
		3.1.3.3 Drug Preparation for Euthanization	
		(Termination Phase)	21
	3.1.4	Animals	21
	5.1.1	3.1.4.1 Selection of Animals	21
		3.1.4.2 Experimental Animals	21
3.2	Mathe	bology	25
5.2	3.2.1	Body Weight, Body Mass Index (BMI) and Percentage	25
	5.2.1	of Body Weight Gain (%)	25
	3.2.2	Anesthetized and Dissection of Rats	26
			20 27
		Biochemical Analysis	
	3.2.4	Histopathological Examination (HPE) Analysis	27
		3.2.4.1 Fixation	27
		3.2.4.2 Tissue Processing	27
		3.2.4.3 Paraffin Wax Embedding	28
		3.2.4.4 Section Cutting	28
		3.2.4.5 Staining	29
	3.2.5	Scanning Electron Microscope (SEM)	29
	3.2.6	Statistical Analysis	30
	IT TO		
4 RESU			31
4.1	Introd		31
4.2		of HFD induction on Sprague Dawley rats	32
		Effect of HFD induction on body weight	33
		Effect of HFD induction on body mass index (BMI)	34
	4.2.3	Effect of HFD induction on percentage body weight	
		gain (%)	34
4.3		of orlistat or stingless bee honey (SBH) interventions on	
		nduced rats, in comparison to normal rats	35
		Effect of interventions on body weight	35
	4.3.2	Effect of intervention on body mass index (BMI)	36
	4.3.3	Effect of intervention on percentage of body weight	37
	4.3.4	Effect of intervention on food intake in comparison to	
		normal rats	38
	4.3.5	Effect of intervention on relative organ weight (ROW)	
		of liver and adiposity index (%)	40
4.4	Effect	of orlistat or stingless bee honey (SBH) interventions on	
	HFD i	nduced obese rats, in comparison to control obese rats	42
	4.4.1	Effect of intervention on body weight	42
	4.4.2	Effect of intervention on body mass index (BMI)	43
	4.4.3	Effect of intervention on percentage of body weight gain	44
	4.4.4	Effect of intervention on food intake	45
	4.4.5	Effect of intervention on relative organ weight (ROW)	-
		of liver and adiposity index (%)	46
		· · · · · · · · · · · · · · · · · · ·	

	4.5	Serum biochemical analysis after intervention using different treatments and dosages of stingless bee honey (SBH) or orlistat,	
		in comparison to normal rats	48
		4.5.1 Liver enzymes	48
		4.5.2 Lipid profile	53
	4.6	Serum biochemical analysis after intervention using different	
		treatments and dosages of stingless bee honey (SBH) or orlistat,	
		in comparison to control obese rats	56
		4.6.1 Liver enzymes	56
		4.6.2 Lipid profile	59
	4.7	Effect daily administration of different treatments and dosages of stingless bee honey (SBH) or orlistat in protecting	
		morphology and histological of liver, aorta and adipose tissue	61
		4.7.1 Observations under light microscopy after H&E staining	62
		4.7.2 Observations under Scanning Electron Microscope (SEM)	74
5	DISC	USSION	81
U	5.1	INTRODUCTION	81
	5.2	High Fat Diet Induction in Experimental Animals (HFD: 32%	
		Cholesterol)	81
	5.3	Treatment and different dosages of Stingless Bee Honey (SBH)	
		administered in experimental animals	84
	5.4	Effect of serum biochemical analysis, liver enzymes and lipid profile in all experimental rats administered by different	
		treatments and dosages of stingless bee honey (SBH)	86
	5.5	Effect of daily administration of different treatments and	
		dosages of stingless bee honey (SBH) on the morphology and	00
		histology of liver, aorta and adipose tissue	90
6	SUMI	MARY AND CONCLUSIONS	93
	6.1	Conclusion	93
	6.2	Limitation and Future Work	93
	6.3	Impact of Study	94
REFF	RENC	TES	96
	NDICI		112
		<b>DF STUDENT</b>	144

xii

# LIST OF TABLES

Table		Page
2.1	Initially Approved Pharmacotheraphy and their current status	5
3.1	List of drugs used for the treatment and their dosage	20
3.2	Full procedure for Tissue Processing in Scanning Electron Microscope	30

# LIST OF FIGURES

	Figure		Page
	2.1	Chemical Structure of Orlistat	6
	2.2	Orlistat (Xenical) acts as positive control (anti-obesity)	6
	2.3	Mechanism of Orlistat as anti-obesity agent	8
	2.4	Degradation process of fats (triglycerides)	8
	2.5	Lipid exchanges between gut, adipose tissue, skeletal muscle and liver	10
	2.6	Regulation and action of LPL	10
	3.1	HFD; 32% cholesterol presented in marble shape	20
	3.2	Oral gavage technique for daily 6 weeks	22
	3.3	Full procedure of study	23
	3.4	Study Design	24
	3.5	BMI Calculation	25
	3.6	Calculation for percentage of body weight gain	25
	3.7	Calculation of relative organ weight (ROW)	26
	3.8	Calculation for adiposity index (%)	26
	4.1	Effect of high-fat diet (Group 2-8) normalises to normal diet (Group 1) on body weight within 6 weeks	32
	4.2	Effect of high-fat diet (Group 2-8) normalises to normal diet (Group 1) on body mass index (BMI) within 6 weeks	33
	4.3	Effect of high-fat diet (Group 2-8) normalises to normal diet (Group 1) on percentage body weight gain within 6 weeks	34
	4.4	Effect of different treatments and dosages (of stingless bee honey or orlistat) on body weight of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)	35

- 4.5 Effect of different treatments and dosages (of stingless bee honey or 36 orlistat) on body mass index (BMI) of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.6 Effect of different treatments and dosages (of stingless bee honey or 37 orlistat) on percentage body weight gain of HFD- induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rat (Group 1)
- 4.7 Effect of high fat diet versus normal diet on food intake over period 38 of 6 weeks during intervention phase
- 4.8 Effect of different treatments and dosages (of stingless bee honey or 39 orlistat) on total food intake of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.9 Effect of different treatments and dosages (of stingless bee honey or 40 orlistat) on relative organ weight (ROW) of liver of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.10 Effect of different treatments and dosages (of stingless bee honey or 41 orlistat) on adiposity index of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.11 Effect of different treatments and dosages (of stingless bee honey or 42 orlistat) on body weight of HFD-induced obese rats different groups of daily treatment for 6 weeks in comparison to control obese rats (group 2)
- 4.12 Effect of different treatments and dosages (of stingless bee honey or 43 orlistat) on body mass index (BMI) of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to control obese rats (group 2)
- 4.13 Effect of different treatments and dosages (of stingless bee honey or 44 orlistat) on percentage body weight gain of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rat (Group 2)
- 4.14 Effect of different treatments and dosages (of stingless bee honey or 45 orlistat) on total food intake of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rats (Group 2)

- 4.15 Effect of different treatments and dosages (of stingless bee honey or 46 orlistat) on relative organ weight (ROW) of liver of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rats (Group 2)
- 4.16 Effect of different treatments and dosages (of stingless bee honey or orlistat) on adiposity index of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rats (Group 2)
- 4.17 Effect of different treatments and dosages (of stingless bee honey or 48 orlistat) on total protein of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.18 Effect of different treatments and dosages (of stingless bee honey or 49 orlistat) on albumin of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1) and control obese rats (Group 2)
- 4.19 Effect of different treatments and dosages (of stingless bee honey or 49 orlistat) on globulin of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to normal rats (Group 1)
- 4.20 Effect of different treatments and dosages (of stingless bee honey or 50 orlistat) on total bilirubin of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to normal rats (Group 1)
- 4.21 Effect of different treatments and dosages (of stingless bee honey or 51 orlistat) on AST of HFD-induced obese rats in different groups of daily treatment for 6 weeks when compared to normal rats (Group 1)
- 4.22 Effect of different treatments and dosages (of stingless bee honey or 51 orlistat) on ALT of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.23 Effect of different treatments and dosages (of stingless bee honey or 52 orlistat) on alkaline phosphatase of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to normal rats (Group 1)
- 4.24 Effect of different treatments and dosages of (stingless bee honey or 53 orlistat) on total cholesterol of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to normal rats (Group 1)

- 4.25 Effect of different treatments and dosages (of stingless bee honey or 54 orlistat) on triglycerides of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to normal rats (Group 1)
- 4.26 Effect of different treatments and dosages (of stingless bee honey or 54 orlistat) on LDL-Cholesterol of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to normal rats (Group 1)
- 4.27 Effect of different treatments and dosages (of stingless bee honey or 55 orlistat) on HDL-Cholesterol of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to normal rats (Group 1)
- 4.28 Effect of different treatments and dosages (of stingless bee honey or 56 orlistat) on albumin of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rats (Group 2)
- 4.29 Effect of different treatments and dosages (of stingless bee honey or 57 orlistat) on AST of HFD-induced obese rats in different groups of daily treatment for 6 weeks when compared to control obese rats (Group 2)
- 4.30 Effect of different treatments and dosages (of stingless bee honey or 58 orlistat) on ALT of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rats (Group 2)
- 4.31 Effect of different treatments and dosages (of stingless bee honey or 58 orlistat) on alkaline phosphatase of HFD-induced obese rats in different groups of daily treatment for 6 weeks, in comparison to control obese rats (Group 2)
- 4.32 Effect of different treatments and dosages (of stingless bee honey or 59 orlistat) on triglycerides of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to control obese rats (Group 2)
- 4.33 Effect of different treatments and dosages (of stingless bee honey or 60 orlistat) on LDL-Cholesterol of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to control obese rats (Group 2)
- 4.34 Effect of different treatments and dosages (of stingless bee honey or 60 orlistat) on HDL-Cholesterol of HFD-induced obese rats in different groups of daily treatment for 6 weeks in comparison to control obese

rats (Group 2)

- 4.35 Morphology images are showing the effect of different treatments and 62 dosages of stingless bee honey or orlistat on liver in obese rats
- 4.36 The effect of different treatments and dosages of stingless bee honey 65 or orlistat on liver of obese rats under light microscope using H&E staining
- 4.37 The effects of different treatments and dosages of stingless bee honey 71 or aorta on aorta of obese rats under light microscope using H&E staining
- 4.38 The effects of different treatments and dosages of stingless bee honey 74 or orlistat on visceral fatty tissue histology of obese rats under light microscope using H&E staining
- 4.39 The effect of different treatments and dosages of stingless bee honey 76 or orlistat in liver tissue of obese rats under Scanning Electron Microscope (SEM)
- 4.40 The effects of different treatments and dosages of stingless bee honey 80 or orlistat on a thoracic aorta surface of obese rats under Scanning Electron Microscopy (SEM)
- 5.1 Physiology of obesity, adapted from Birari and Bhutani, (2007). LPA: 80 lysophosphatidic acid, TG: triglyceride, FA: fatty acids and MG: monoglycerides

# LIST OF ABBREVIATIONS

FA		Fatty Acids
HD	DL	High-Density Lipoprotein
H&	έE	Hematoxylin & Eosin
HF	Ð	High Fat Diet
HP	ΡE	Histopathological Examination
IP		Intraperitonial
LD	DL	Low-Density Lipoprotein
LP	L	Lipoprotein Lipase
MO	DA	Mechanism of Action
NA	AFLD	Non-Alcoholic Fatty Liver Disease
ND		Normal Diet
OS	5	Oxidative Stress
RC	DS	Reactive Oxygen Species
RO	W	Relative Organ Weight
SD		Sprague-Dawley
SB	н	Stingless Bee Honey
SE	М	Scanning Electron Microscope
TG	ł	Triglyceride

## **CHAPTER 1**

#### **INTRODUCTION**

### 1.1 Obesity

Obesity is one type of disease that increase among people globally and spread by increasing urbanization. Haslam and James (2005) have stated that rapidly growing epidemic worldwide of this problem may lead to the negative effect on health, which risk to reduce life expectancy and /or increase health problem. Approximately 2.8 million deaths happended per year due to the uncontrolled obesity according to the World Health Organization (WHO) 2013. Due to this, it has been listed as the fifth risk factor for mortality and morbidity around the world (WHO, 2013). Statistically, in year of 2014, it was reported that 1.9 billion adults (18 years and above) worldwide were overweight. More than 600 million from this range or about 13% of the world's adult population s (11% of men and 15% of women) were facing obesity problem (WHO, 2015). Fatimah *et al* (2005) have mentioned that in Malaysia, 23% of the adult population was found to be overweight and 14% was obese. Based form this data, it can be highlighted that Malaysia has been rated as the highest among Asian countries for obesity (Bernama, 2014).

Obesity has been defined as excessive or abnormal fat accumulation that is detrimental to human health, whereby there is an increase in adipose tissue mass as a result of an enlargement and increase number of fat cells. Obesity measurement can be calculated by Body Mass Index (BMI), calculated as body weight in kilogram divided by the square of height in meters. Range of BMI between 25-29.9 kgm<sup>-2</sup> categorised as overweight and BMI exceeding 30kgm<sup>-2</sup> is considered as obese (WHO, 2015).

Individuals who have BMI greater or equal to 30 are more likely to have health complication problems which include hyperlipidemia, cardiovascular disease, high blood pressure, diabetes, stroke, arthritis, cancer, breathing problems and metabolic syndrome (Nguyen *et al.*, 2009). However, the most relevant disease which affect from obesity complication are high blood pressure, diabetes mellitus and cardiovascular diseases (Malnick and Knobler, 2006; Pagotto *et al.*, 2008; Kurukulasuriya *et al.*, 2011).

#### **1.2** Stingless Bee Honey (*Heterotrigona itama* species)

Generally, stingless bees can be found in most of tropical and subtropical regions around the world such as Africa, Southeast Asia, Australia and South America. There are more than 500 species described including 32 genera worldwide with perhaps more than 100 new species to be characterized (Chuttong *et al.*, 2014). Eighty nine species in 15 genera from the Indo/Australian region has been listed



(Rasmussen, 2008) meanwhile in Thailand, 32 species of stingless bees in 10 genera have been identified (Chuttong *et al.*, 2014). Before the production of honey, floral nectars were collected, stored and chemically modified by social bees. Unlike western honey bee *Apis mellifera*, they produce and store much more honey compared to stingless bees and it become world leader in honey production. In Thailand, it was estimated that total national production of stingless bee honey to be 2.5-3 metric tons which is lower compared to honey from *A. mellifera* (Chuttong *et al.*, 2014). Hence, this limited production results in lack of quality standard of stingless bee honey and insufficient knowledge and unregulation by food control authorities leads to the exclusion from international standards (Chuttong *et al.*, 2014).

To expand the knowledge with scientific research related to stingless bee honey, the aim of this study was to evaluate the effect of stingless bee honey from H. *itama* species to obese rat model. The work includes evaluating the effects of different dosages of stingless bee honey on weight, lipid profile, liver function test, and histopathology of liver and aorta in each respected groups of treated and untreated rats. This finding would create the path for further studies, in order to produce medicinal product from this natural medicine with acceptable levels of safety, efficacy and tolerability especially in the management of obesity and also as preventive medicine against several degenerative diseases such as liver disease, blood pressure etc.

## 1.3 Objectives

#### **1.3.1 General Objective**

• To investigate the therapeutic effect of stingless bee honey in obesity and complication risks associated with obesity in rat model of obesity.

# **1.3.2** Specific Objectives

- To determine the body weight, body mass index (BMI), percentages of body weight gain (%), and food intake of all treated and untreated obese rats.
- To evaluate the biochemistry parameters including lipid profile and liver function test between treated and untreated obese rats.
- To evaluate the histopathological changes of organ structures (liver, aorta and adipose tissue) in treated and untreated obese rats.

## 1.4 Hypothesis

• Stingless bee honey is able to reduce the weight and other complication risks associated with obesity in diet-induced rats.

#### REFERENCES

- Abo Elnaga NIE, Massoud, M. I., Yousef MI, Mohamed HHA. (2006). Effect of stevia sweetener consumption as non-caloric sweetening on body weight gain and biochemical's parameters in overweight female rats. Annals of Agricultural Sciences; 61:155–163.
- Ace Animals Inc. (2007). Sprague Dawley. Retrieved on 26th July 2016 at <a href="http://aceanimals.com/SpragueDawley.htm">http://aceanimals.com/SpragueDawley.htm</a>.>
- Alia, M., Horcajo, C., Bravo, L. & Goya, L. (2003). Effect of grape antioxidant dietry fiber on the total antioxidant capacity and the activity of liver antioxidant enzymes in rats. *Nutrition Research*, 23: 1251–1267.
- Aljadi, A. M., & Kamaruddin, M. Y. (2004). Evaluation of the phenolic contents and antioxidant capacities of two Malaysian floral honeys. *Food Chemistry*, 85(4), 513–518.
- Almeida-Muradian, L. B. (2013). Tetragonisca angustula pot-honey compared to Apis mellifera honey from Brazil. In P. Vit et al. (Eds.), Pot-honey a legacy of stingless bees (pp. 375–382). New York: Springer.
- Almind, K. & Kahn, C. R. (2004). Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. *Diabetes*, 53: 3274–3285.
- Altunkaynak, B. Z. & Özbek, E. (2009). Overweight and structural alterations of the liver in female rats fed a high-fat diet: A stereological and histological study. *The Turkish. Journal of Gastroenterology*, 20: 93-103.
- Alvarez-Suarez, J. M., Giampieri, F., Gonzalez-Paramas, A. M., Damiani, E., Astolfi, P., Martinez-Sanchez, G., et al. (2012). Phenolics from monofloral honeys protect human erythrocyte membranes against oxidative damage. *Food and Chemical Toxicology*, 50, 1508–1516.
- Anacleto DA, Souza BA, Marchini LC, Moreti ACCC. (2009). Composition of Jatai bee honey samples (Tetragonisca angustula Latreille, 1811). Food Science and Technology.;29(3):535-541.
- Angulo, P. (2002). Nonalcoholic fatty liver disease. *New England Journal of Medicine*, 346(16): 1221-1231.
- Anstee, Q. M., Targher, G. & Day, C. P. (2013). Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, 10(6): 330-344.

- Atcha, Z., Rourke, C., Neo, A. H, Goh, C. W., Lim, J. S., Aw, C., Browne, E. R. & Pemberton, D. J. (2010). Alternative Method of Oral Dosing for Rats. *Journal of the American Association Laboratory Animal Science*, 49(3): 335– 343.
- Babin, P. J. & Gibbons, G. F. (2009). The evolution of plasma cholesterol: direct utility or a "spandrel" of hepatic lipid metabolism? *Progress in lipid research*, 48(2): 73-91.
- Bahrami M, Ataie-Jafari A, Hosseini S, Foruzanfar H, Rahmani M, Pajouhi M.(2009). Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. Int J Food Sci Nutr ;60: 618-26.
- Bełtowski, J. (2012). Review: Leptin and the regulation of endothelial function in physiological and pathological conditions. *Clinical and Experimental Pharmacology and Physiology*, 39(2): 168-178.
- Bernama. (2014). Malaysia's obesity rate highest in Asia. The Star 16 June 2014. Retrieved on 1<sup>st</sup> June 2016 at <a href="http://www.thestar.com.my/News/Nation/2014/06/16/obesity-malaysia-highest-in-asia-says-pm-science-advisor/">http://www.thestar.com.my/News/Nation/2014/06/16/obesity-malaysia-highest-in-asia-says-pm-science-advisor/</a>
- Beretta, G., Granata, P., Ferrero, M., Orioli, M., Facino, R.M. (2005). Standardization of Antioxidant Properties of Honey by a Combination of Spectrophotometric/Fluorimetric Assays and Chemometrics. *Analytica Chimica Acta*, 533; 185-191.
- Bhandari, U., Chaudhari, H. S., Bisnoi, A. N., Kumar, V., Khanna, G., & Javed, K. (2013). Anti-obesity effect of standardized ethanol extract of Embelia ribes in murine model of high fat diet-induced obesity. *PharmaNutrition*, 1(2), 50– 57.
- Bhatia, L. S., Curzen, N. P., Calder, P. C. & Byrne, C. D. (2012). Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? *European Heart Journal*, 33(10): 1190-1200.
- Bhurosy, T. & Jeewon, R. (2013). Pitfalls of using body mass index (BMI) in assessment of obesity risk. *Current Research in Nutrition and Food Science Journal*, 1(1): 71-76.
- Biddinger, S. B., Almind, K., Miyazaki, M., Kokkotou, E., Ntambi, J. M. & Kahn, C. R. (2005). Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. *Diabetes*, 54(5): 1314-1323.

- Biluca, F. C., Della Betta, F., De Oliveira, G. P., Pereira, L. M., Gonzaga, L. V., Costa, A. C. O., & Fett, R. (2014). 5-HMF and carbohydrates content in stingless bee honey by CE before and after thermal treatment. *Food Chemistry*, 159, 244–249.
- Birari, R. B., Gupta, S., Mohan, C. G. & Bhutani, K. K. (2011). Antiobesity and lipid lowering effects of *Glycyrrhiza chalcones*: experimental and computational studies. *Phytomedicine*, 18(8-9): 795-801.
- Block, J. P., Scribner, R. A. & DeSalvo, K. B. (2004). Fast food, race/ethnicity, and income. A geographical analysis. *American Journal of Preventive Medicine*, 27: 211-217.
- Bondia-Pons, I., Ryan, L. & Martinez, J. A. (2012). Review: Oxidative stress and inflammation interactions in human obesity. *Journal of Physiology and Biochemistry*, 68(4): 701-11.
- Boone, L. R., Brooks, P. A., Niesen, M. I. & Ness, G. C. (2011). Mechanism of resistance to dietary cholesterol. *Journal of Lipids*, 2011.
- Bowman, S. A., Gortmaker, S. L., Ebbeling, C. B., Pereira, M. A. & Ludwig, D. S. (2004). Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. *Pediatrics*, 113: 112-118.
- Bray, G. A. (2000). A concise review on the therapeutics of obesity. *Nutrition*, 16: 953-960.
- Bray, G. A. (2001). Drug treatment of obesity. *Reviews in Endocrine and Metabolic Disorders*, 2: 403–418.
- Bray, G. A., and Tartaglia, L. A. (2000). Medicinal strategies in the treatment of obesity. *Nature*, 404: 672-677.
- Buettner, R., Parhofer, K., Woenckhaus, M., Wrede, C. E., Kunz-Schughart, L. A., Schölmerich, J. & Bollheimer, L. C. (2006). Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. *Journal of Molecular Endocrinology*, 36: 485–501.
- Buettner, R., Scholmerich, J. & Bolheimer, L. C. (2007). High-fat diets: modeling the metabolic disorders of human obesity in rodents. *Obesity*, 15(4):798–808.
- Cao, G., Sofic, E., & Prior, R. L. (1997). Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. *Free Radical Biol. Med*, 22; 749– 760.
- Carter, R., Mouralidarane, A., Ray, S., Soeda, J. & Oben, J. (2012). Recent advancements in drug treatment of obesity. *Clinical Medicine*, 12(5): 456-460.

- Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M. & Sanyal, A. J. (2012). The diagnosis and management of non- alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *American Journal of Gastroenterology*, 55(6): 2005-2023.
- Chanchao, C. (2009). Antimicrobial activity by Trigona laeviceps (stingless bee) honeyfrom Thailand. Pak. J. Med. Sci. 25, 364–369.
- Chandra, M. S., Balamurugan, V., Thiripura, S. & Rekha, R. (2012). Metal ion chelating activity and hydrogen peroxide scavenging activity of medicinal plant *Kalanchoe pinnata*. *Journal of Chemistry and Pharmaceutical Research*, 4: 197-202.
- Chapman, M. J. (2003). Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. *Atherosclerosis*, 171: 1–13.
- Chanoine, J.-P., Hampl, S., Jensen, C., Boldrin, M. & Hauptman, J. (2005). Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. *JAMA*, 293(23): 2873-2883.
- Chaput, J. P. & Tremblay, A. (2007). Current and novel approaches to the drug therapy of obesity. *European Journal of Clinical Pharmacology*, 62(10): 793-803.
- Chepulis, L. M. (2007). The effect of honey compared to sucrose, mixed sugars, and a sugar-free diet on weight gain in young rats. *Journal of Food Science*, 72(3), 224–229.
- Chepulis L and Starkey L.(2008). The long-term effects of feeding honey compared with sucrose and a sugar-free diet on weight gain, lipid profiles, and DEXA measurements in rats. J Food Sci ;73:H1-7.
- Chitturi, S. (2008). Treatment options for nonalcoholic fatty liver disease. *Therapeutic Advances in Gastroenterology*, 1(3): 173–189.
- Chiu, C.-Y., Chang, T.-C., Liu, S.-H., & Chiang, M.-T. (2017). The regulatory effects of fish oil and chitosan on hepatic lipogenic signals in high-fat diet-induced obese rats. *Journal of Food and Drug Analysis*, xxx, 1-12.
- Chrysohoou, C., Panagiotakos, D. B., Pitsavos, C., Skoumas, I., Papademetriou, L., Economou, M. & Stefanadis, C. (2007). The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. *Nutrition, Metabolism and Cardiovascular Diseases*, 17(8): 590-597.

- Chuttong, B., Chanbang, Y., & Burgett, M. (2014). Meliponiculture stingless bee beekeeping in Thailand. *Bee World*, 91(2), 41–45.
- Cudrey, C., van Tibeurgh, H., Gargouri, Y. & Verger, R. (1993). Inactivation of pancreatic lipase by amphiphlic reagents 5-(dodecyldithio)-2-nitrobenzoic acid and tetrahydrolipstatin. Dependence upon partitioning between micllar and oil phases. *Biochemistry*, 32: 800-808.
- De Moura RF, Ribeiro C, deOliveira JA, Stevanato E, de Mello MA.(2009). Metabolic syndrome signs in Wistar rats submitted to different high fructose ingestion protocols. Br J Nutr;101:1178-85.
- Doggrell, S. (2005). Clinical evidence for drug treatments in obesity-associated hypertensive patients—a discussion paper. *Methods and Findings in Experimental and Clinical Pharmacology*, 27(2): 119-125.
- Drent, M. L. & Veen, E. A. (1995). First clinical studies with orlistat: a short review. *Obesity Research*, 3(S4): 623S-625S.
- Drury, V. W., Wade, O. L. & Woolf, E. (1976). Following advice in general practice. *The Journal of the Royal College of General Practitioners*, 26(171): 712-718.
- El Denshary, E,S., Al-Gahazali, M,A., Mannaa, F,A., Salem, H,A., Hassan, N,S., Abdel-Wahhab, M,A. (2011). Dietary honey and ginseng protect against carbon tetrachloride-induced hepatonephrotoxicity in rats. *Exp. Toxicol. Pathol*, 21; 1-8.
- Erejuwa, O,O., Sulaiman, S,A., Wahab, M,S., Sirajudeen, K,N., Salleh, M,S., Gurtu, S. (2009). Effects of Malaysian tualang honey supplementation on glycemia, free radical scavenging enzymes and markers of oxidative stress in kidneys of normal and streptozotocin-induced diabetic rats. *Int. J. Cardiol.* 137; S45.
- Erejuwa, O.O.; Gurtu, S.; Sulaiman, S.A.; Ab Wahab, M.S.; Sirajudeen, K.N.; Salleh, M.S. (2010). Hypoglycemic and antioxidant effects of honey supplementation in streptozotocin-induced diabetic rats. *Int. J. Vitam. Nutr*, 80; 74–82.
- Erejuwa, O.O., Sulaiman, S.A., Wahab, M.S., Sirajudeen, K.N.S., Salleh, M.S., and Gurtu, S. (2011). "Hepatoprotective effect of tualang honey supplementation in streptozotocin-induced diabetic rats," *International Journal of Applied Research in Natural Products*, vol. 4, no. 4, pp. 37–41.
- Fallico, B. Zappal, M. Arena, E. Verzera, A. (2004). Effects of heating process on chemical composition and HMF levels in Sicilian monofloral honeys. *Food Chem*, 85; 305.

- Fatimah, S., Tahir, A., Siti, S. H. N. & Maimunah, A. H. (2005). Nutritional status of adults aged 18 years and above. national health and morbidity survey 2001/2002, Public Health Institute, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
- Favier, A. (2003). The oxidative stress: concept and experimental interest to understand diseases mechanisms and therapeutic approaches. *Chemical News*, 108-115.
- Fernández-Sánchez, A., Madrigal-Santillán, E., Bautista, M., Esquivel-Soto, J., Morales-González, Á., Esquivel-Chirino, C., Durante-Montiel, I., Sánchez-Rivera, G., Valadez-Vega, C. & Morales-González, J. A. (2011). Inflammation, oxidative stress, and obesity. *International Journal of Molecular Sciences*, 12(5): 3117-3132.
- Foxcroft, D. R., & Milne, R. (2000). Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. *Obesity Reviews : An Official Journal* of the International Association for the Study of Obesity, 1(2), 121–126.
- Frayn, K. N. (2002). Review Adipose tissue as a buffer for daily lipid flux. *Diabetologia*, 45(9): 1201-1210.
- Frayn, K.N. (2003) Metabolic Regulation: a Human Perspective, 2nd edn. Published by Blackwell Publishing.
- Gajda, A. M. (2008). High fat diets for diet-induced obesity models. *Research Diets*, 15: 798-808.
- Gajda, A. M., Pellizzon, M. A., Ricci, M. R. & Ulman, E. A. (2007). Diet-induced metabolic syndrome in rodent models. *Animal Lab News*, 74: 775-793.
- Galaly, S. R., Hozayen, W. G., Amin, K. A. & Ramadan, S. M. (2014). Effects of Orlistat and herbal mixture extract on brain, testes functions and oxidative stress biomarkers in a rat model of high fat diet. *Beni-Suef University Journal* of Basic and Applied Sciences, 3(2): 93-105.
- Garba, A. (2012). "The effects of honey and aloe vera extract on ibuprofen induced liver damage in rats," *IOSR Journal of Pharmacy and Biological Sciences*, vol. 3, no. 2, pp. 6–10.
- Garedew, A., Schmolz, E., & Lamprecht, I. (2003). The Antimicrobial Activity of Honey of the Stingless Bee Trigona spp. *Journal of Apicultural Science*, 47(1), 37–49.
- Ghibaudi, L., Cook, J., Farley, C., van Heek, M. & Hwa, J. J. (2002). Fat intake affects adiposity, comorbidity factors, and energy metabolism of Sprague–Dawley rats. *Obesity Research*, 10: 956–963.

- Goodman, Z. D. (2014). The impact of obesity on liver histology. *Clinics in Liver Disease*, 18(1): 33-40.
- Guerciolini, R. (1997). Mode of action of orlistat. *International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity*, 21: S12-23.
- Ha, S., Ca, S.-T., Rb, R. & KPb, J. (2012). Socio-demographic, dietary and physical activity determinants of adolescents overweight and obesity in Kelantan. *Health and the Environment Journal*, 3(1): 44-53.
- Hadvary, P., Lengsfeld, H. & Wolfer, H. (1988). Inhibition of pancreatic lipase *in vitro* by the covalent inhibitor tetrahydrolipstatin. *Biochemical Journal*, 256: 357-361.
- Hallsworth, K., Hollingsworth, K. G., Thoma, C., Jakovljevic, D., MacGowan, G. A., Anstee, Q. M., Taylor, R., Day, C. P. & Trenell, M. I. (2013). Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. *Journal of Hepatology*, 58(4): 757-762.
- Haslam, D. W. & James, W. P. (2005). Obesity. Lancet. 366 (9492): 1197-1209.
- Hegazi, A.G., F.K. Abd El Hady. (2009). Influence of Honey on the Suppression of Human Low Density Lipoprotein (LDL) Peroxidation (In vitro). Journal of Evidence Based Complementary and Alternative Medicine, 6(1): 113-121.
- Herrera-Arellano, A., Miranda-Sánchez, J., Ávila-Castro, P., Herrera-Álvarez, S., Jiménez-Ferrer, J. E., Zamilpa, A., Román-Ramos, R., Ponce-Monter, H. & Tortoriello, J. (2007). Clinical effects produced by a standardized herbal medicinal product of *Hibiscus sabdariffa* on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. *Planta medica*, 73(1): 6-12.
- Higdon, J. & Frei, B. (2003). Obesity and oxidative stress: A direct link to CVD? Arteriosclerosis, Thrombosis and Vascular Biology, 23: 365–367.
- Hirunpanich, V., Utaipat, A., Morales, N.P., Bunyapraphatsara, N., Sato, H., Herunsale, A. & Suthisisang, C. (2006). Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of *Hibiscus* sabdariffa L. in hypercholesterolemic rats. Journal of Ethnopharmacology, 103: 252–260.
- Hoggatt, A. F., Hoggatt, J., Honerlaw, M. & Pelus, L. M. (2010). A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice. *Journal of the American Association for Laboratory Animal Science: JAALAS*, 49(3): 329.

- Huang, L., Chen, J., Cao, P., Pan, H., Ding, C., Xiao, T., Zhang, P., Guo, J., and Su, Z.(2015). Anti-Obese Effect of Glucosamine and Chitosan Oligosaccharide in High-Fat Diet-Induced Obese Rats. *Journal of marine drugs*. 2, 2732– 2756.
- Ioannides-Demos, L. L., Piccenna, L. & McNeil, J. J. (2010). Pharmacotherapies for obesity: past, current, and future therapies. *Journal of Obesity*, 2011.
- Iossa, S., Lionetti, L., Mollica, M., Barletta, A. & Liverini, G. (1999). Energy intake and utilization vary during development in rats. *Journal of Nutrition*, 129: 1596–1598.
- Islam, M.Z., Khalil, M.I., Islam, M.A., Siew, H.G. (2013). Toxic compounds in honey. *Journal of Applied Toxicology*, 34; 733-742.
- Johnson, M. D. (2007). The rat: Gad, S. C., editor. *Animal models in toxicology*. Boca Raton (FL): CRC Press, 150–193.
- Kao, Y.H., Hiipakka, R.A., Liao, S. (2000). Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. *Endocrinology*, 141; 980-987.
- Kaskoniene, V., Venskutonis, P.R. (2010). Floral Markers in Honey of Various Botanical and Geographical Origins: A Review. *Comprehensive Reviews in Food Science and Food Safety*, 9. 620-634.
- Kasote, D. M., Hegd, M. V. & Deshmukh, K. K. (2011). Antioxidant Activity of Phenolic Components from n-Butanol Fraction (PC-BF) of Defatted Flaxseed Meal. American Journal of Food Technology, 6: 604-612.
- Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J. & Hollander, P. (2002). Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. *Diabetes Care*, 25(6): 1033-1041.
- Khalil, M.I., Mahaneem, M., Jamalullail, S.M.S., Alam, N., Sulaiman, S.A. (2011). Evaluation of Radical Scavenging Activity and Colour Intensity of Nine Malaysian Honeys of Different Origin. *Journal of ApiProduct and ApiMedical Science*. 3; 4-11.
- Khalil, M.I., Sulaiman, S.A., Boukraa, L. (2010). Antioxidant properties of honey and its role in preventing health disorders. *Open Nutraceuticals Journal*, 3; 6-16.
- Khan, N. I., Naz, L., Yasmeen, G. & Pak, J. (2006). Obesity: an independent risk factor for systemic oxidative stress. *Journal of Pharmaceutical Sciences*, 19(1): 62-65.

- Kiki, I., Altunkaynak, B.Z., Altunkaynak, M.E., Vuraler, O., Unal, D. & Kaplan, S. (2007). Effect of high fat diet on the volume of liver and quantitative feature of kupffer cells in the female rat: A stereological and ultrastructural study. *Obesity Surgery*, 17: 1381-1388.
- Kim, K. H. & Park, Y. (2011). Food components with anti-obesity effect. *Annual Review of Food Science and Technology*, 2: 237-257.
- Kopelman, P. G. (2000). Obesity as a medical problem. *Nature*, 404(6778): 635-643.
- Kurukulasuriya, L. R., Stas, S., Lastra, G., Manrique, C. & Sowers, J. R. (2011). Hypertension in obesity. *The Medical Clinics of North America*, 95(5): 903-917.
- Landmesser, U. & Harrison, D. G. (2001). Oxidative stress and vascular damage in hypertension. *Coronary Artery Disease*, 12(6): 455-461.
- Lindner, J. R., Song, J., Christiansen, J., Klibanov, A. L., Xu, F. & Ley, K. (2001). Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. *Circulation*, 104: 2107–2112.
- Lindner, J. R., Song, J., Xu, F., Klibanov, A. L., Singbartl, K., Ley, K. & Kaul, S. (2000). Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. *Circulation*, 102: 2745–2750.
- Loannidou, M.D., Zachariadis, G.A., Anthemidis, A.N., Stratis, J.A. (2004). Direct determination of toxic trace metals in honey and sugars using inductively coupled plasma atomic emission spectrometry. *Talanta*, 65;92–97.
- Madeira, I. R., Carvalho, C. N., Gazolla, F. M., Pinto, L. W., Borges, M. A. & Bordallo, M. A. N. (2009). Impact of obesity on metabolic syndrome components and adipokines in prepubertal children. *Jornal de pediatria*, 85(3): 261-268.
- Malik, V. S., Willett, W. C. & Hu, F. B. (2013). Global obesity: trends, risk factors and policy implications. *Nature Reviews Endocrinology*, 9(1): 13-27.
- Malnick, S. D. H., & Knobler, H. (2006). The medical complications of Obesity. *QJM: An International Journal of Medicine*, 99(9): 565-579.
- Mamikutty, N., Thent, Z. C., Sapri, S. R., Sahruddin, N. N., Mohd Yusof, M. R. & Haji Suhaimi, F. (2014). The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. *BioMed Research International*, 21: 11-19.
- Marchesini, G., Moscatiello, S., Di Domizio, S. & Forlani, G. (2008). Obesityassociated liver disease. *The Journal of Clinical Endocrinology & Metabolism*, 93(11\_supplement\_1): s74-s80.

- Matsumoto, S., Gotoh, N., Hishinuma, S., Abe, Y., Shimizu, Y., Katano, Y., & Ishihata, A. (2014). The Role of Hypertriglyceridemia in the Development of Atherosclerosis and Endothelial Dysfunction. *Nutrients*, 6(3): 1236–1250.
- Mayor A. (1995). Mad Honey (toxic honey in history). Archaeology, 48(6):32–40.
- Mittendorfer, B., Ostlund, R. E., Patterson, B. W. & Klein, S. (2001). Orlistat inhibits dietary cholesterol absorption. *Obesity*, 9(10): 599-604.
- Mohamed, G. A., Ibrahim, S. R., Elkhayat, E. S. & El Dine, R. S. (2014). Natural anti-obesity agents. *Bulletin of Faculty of Pharmacy, Cairo University*, 52(2): 269-284.
- Musso, G., Gambino, R. & Cassader, M. (2013). Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. *Progress in Lipid Research*, 52(1): 175-191.
- Nascimbeni, F., Pais, R., Bellentani, S., Day, C.P., Ratziu, V., Loria, P. & Lonardo, A. (2013). From NAFLD in clinical practice to answers from guidelines. *Journal of Hepatology*, 59: 859–871.
- Nascimento, A., Marchini, L., Carvalho, C., Araújo, D., Olinda, R., & Silveira, T. (2015). Physical-Chemical Parameters of Honey of Stingless Bee (Hymenoptera: Apidae). *American Chemical Science Journal*, 7(3), 139–149.
- Ness, G. C. & Gertz, K. R. (2004). Hepatic HMG-CoA reductase expression and resistance to dietary cholesterol. *Experimental Biology and Medicine*, 229(5): 412-416.
- Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., ... Gakidou, E. (2014). Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*, 384(9945), 766– 781.
- Nguyen, X. T., Lane, J., Smith, B. R. & Nguyen, N. T. (2009). Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. *The Journal of Gastrointestinal Surgery*, 13: 1205–1212.
- NHS. (2011). The information centre. Statistics on obesity, physical activity and diet: England, 2011. Retrieved on 10<sup>th</sup> August 2016 at <www.ic.nhs.uk/webfiles/publications/003\_Health\_Lifestyles/opad11/Statisti cs\_on\_Obesity\_Physical\_Activity\_and\_Diet\_England\_2011\_revised\_Aug11. pdf>

- NICE. (2006). Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. Retrieved on 10<sup>th</sup> August 2016 at <www.nice.org.uk/nicemedia/live/11000/30365/30365.pdf>
- Nicholls, H. (2001). Roche reveals benefits of Xenical for type 2 diabetics. *Trends in Endocrinology and Metabolism*, 12: 381.
- Nik Norliza, N. H., Tengku Farah Adilah, T. A., Siti Hajar, M., Wan Amir Nizam, W. A. & Wan Rosli, W. I. (2014). Does Extract of Pleurotus sajor-caju affect Liver Enzymes and Histological Integrity? *Annals of Microscopy*, 14: 18-27.
- Novelli, E., Diniz, Y., Galhardi, C., Ebaid, G., Rodrigues, H., Mani, F., Fernandes, A., Cicogna, A. & Novelli Filho, J. (2007). Anthropometrical parameters and markers of obesity in rats. *Laboratory animals*, 41(1): 111-119.
- Oboh, G. & Rocha, J. B. T. (2007). Antioxidant in Foods: A New Challenge for Food Processors. Leading Edge Antioxidants Research, Nova Science Publishers Inc. New York US, 35-64.
- Oddo, L. P., Heard, T. A., Rodrigues-Malayer, A., Perez, R. A., Fernandez-Muino, M., Sancho, M. T., et al. (2008). Composition and antioxidant activity of Trigona carbonaria honey from Australia. Journal of Medicinal Food, 11, 789–794.
- Omotayo O. Erejuwa, Siti A. Sulaiman, Mohd S. Ab Wahab. (2012). Honey: A Novel Antioxidant. *Journal of molecules*. 4400-4423.
- OECD (1996). OECD Guidelines for Testing of Chemical No. 422: Combined Repeated Dose Toxicity Study with The Reproduction/ Developmental Toxicity Test. (Original guideline, adopted 23<sup>th</sup> March 1963).
- OECD (2001). OECD Guidelines for Testing of Chemical No. 414: Prenatal Developmental Toxicity Study. (Proposals for Updating Guidelines 414, adopted 22<sup>nd</sup> January 2001).
- Ok, E., Do, G.-M., Lim, Y., Park, J.-E., Park, Y.-J. & Kwon, O. (2013). Pomegranate vinegar attenuates adiposity in obese rats through coordinated control of AMPK signaling in the liver and adipose tissue. *Lipids in Health and Disease*, 12(163): 1-8.
- Oliveira, P. S., Muller, R. C. S., Dantas, K. G. F., Alves, N. C., Vasconcelos, M. A. M., & Venturieri, G. C. (2012). Phenolic acids, flavonoid and antioxidant activity of honeys of Melipona fasciculata, M. flavolineata Apidae, Meliponini) e Apis mellifera (Apidae, Apini) from Amazon. Química Nova, 15, 200–205.

- Osada, K., Takahashi, M., Hoshina, S., Nakamura, M., Nakamura, S., Sugano, M. (2001). Tea catechins inhibit cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. *Comp Biochem Physiol C Toxicol Pharmacol*, 128; 153-64.
- Padwal, R. S. & Majumdar, S. R. (2007). Drug treatments for obesity: orlistat, sibutramine, and rimonabant. *Lancet*, 369: 71–77.
- Padwal, R., Li, S. & Lau, D. (2003). Long-term pharmacotherapy for obesity and overweight. *Cochrane Database of Systematic Reviews*, 4(4).
- Pagotto, U., Vanuzzo, D., Vicennati, V. & Pasquali, R. (2008). Pharmacological therapy of obesity. *Giornale Italiano di Cardiologia (Rome)*, 9(4 Suppl 1): 83S–93S.
- Park, S. H., Huh, T. L., Kim, S. Y., Oh, M. R., Tirupathi Pichiah, P. B., Chae, S. W., & Cha, Y. S. (2014). Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): A randomized, double-blind, placebo-controlled trial. *Obesity*, 22(1), 63–71.
- Patel, C., Ghanim, H., Ravishankar, S., Sia, C. L., Viswanathan, P., Mohanty, P. & Dandona, P. (2007). Prolonged reactive oxygen species generation and nuclear factor-κB activation after a high-fat, high-carbohydrate meal in the obese. *The Journal of Clinical Endocrinology & Metabolism*, 92(11): 4476-4479.
- Patel, S. (2011). Orlistat Our New OTC Friend for Weight Loss. Mind and Muscle. Retrieved on 9<sup>th</sup> June 2016 at < http://mindandmuscle.net/articles/orlistat-our-new-otc-friend-for-weightloss-by-sitesh-patel/>
- Patricia, V. (2002). Effect of stingless bee honey in selenite induced cataracts. Apiacta3, 1–2.
- Peng, C. -H., Chyau, C. -C., Chan, K. -C., Chan, T. -H., Wang, C. -J. & Huang, C. -N. (2011). *Hibiscus sabdariffa* polyphenolic extract inhibits hyperglycemia, hyperlipidemia, and glycation-oxidative stress while improving insulin resistance. *Journal of Agricultural and Food Chemistry*, 59(18): 9901-9909.
- Petrus, K.; Schwartz, H.; Sontag, G. (2011). Analysis of flavonoids in honey by HPLC coupled with coulometric electrode array detection and electrospray ionization mass spectrometry. *Anal. Bioanal. Chem.* 400; 2555–2563.
- Powell, A., Apovian, C. & Aronne, L. (2011). New drug targets for the treatment of obesity. *Clinical Pharmacology & Therapeutics*, 90(1): 40-51.
- Prasad, K. (2008). Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. *Atherosclerosis*, 197(1): 34-42.

- Przybyowski, P., Wilczynska, A. (2001). Honey as an environmental marker. *Food Chem*, 74; 289–291.
- Rao, M., Raghu, P., Jyothi, Y. & Rabban, S. I. (2015). Anti-obesity activity of *Taraxacum officinale* in high fat diet induced obese rats. *Journal of Chemical* & *Pharmaceutical Research*, 7(4).
- Rao, P.V. and Hua, G.S. (2014). "Rhinacanthus nasutus restores the glycogen and liver functional markers in streptozotocin— induced diabetic rats," Asian Pacific Journal of Tropical Disease, vol. 4, no. 3, p. 232.
- Rasmussen, C. (2008). Catalog of the Indo-Malayan/Australian stingless bees (Hymenoptera: Apidae: Meliponini). (Zootaxa 1935). (80 pp). Auckland: Magnolia Press.
- RifeShare. (2015). Do I have to lose weight? Knowing your BMI. Retrieved on 20<sup>th</sup> May 2017 at <a href="http://www.rifeshare.com/lose-weight-knowing-bmi/">http://www.rifeshare.com/lose-weight-knowing-bmi/</a>
- Roche Laboratories Inc. (2009). XENICAL orlistat capsule. Retrieved on 20<sup>th</sup> May 2017 at <a href="http://www.fda.gov/downloads/UCM205349.pdf">http://www.fda.gov/downloads/UCM205349.pdf</a>>
- Rodgers, R. J., Tschöp, M. H. & Wilding, J. P. (2012). Anti-obesity drugs: past, present and future. *Disease Models & Mechanisms*, 5(5): 621-626.
- Romero-Silva, S., Martinez, R.M.A., Romero-Romero, L.P., Rodriguez, O., Gerardo, G.C.S., and Morel, N. (2011). "Effects of honey against the accumulation of adipose tissue and the increased blood pressure on carbohydrate-induced obesity in rat," *Letters in Drug Design & Discovery*, vol. 8, pp. 69–75.
- Rossmeisl, M., Rim, J. S., Koza, R. A. & Kozak, L. P. (2003). Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. *Diabetes*, 52(8): 1958-1966.
- Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007). Long term pharmacotherapy for obesity and overweight: updated meta-analysis. *British Medical Journal*, 335(7631): 1194-1199.
- Ruxton, C. (2012). "Honey: natural, healthier sweetness," *Nutrition Communication: Research Update*, vol. 81, pp. 1–2.
- RxList Inc. (2015). Xenical. Retrieved on 11<sup>th</sup> June 2015 at <a href="http://www.rxlist.com/xenical-drug.htm">http://www.rxlist.com/xenical-drug.htm</a>
- Samat, S., Kanyan Enchang, F., Nor Hussein, F., & Wan Ismail, W. I. (2017). Four-Week Consumption of Malaysian Honey Reduces Excess Weight Gain and Improves Obesity-Related Parameters in High Fat Diet Induced Obese Rats. *Evidence-Based Complementary and Alternative Medicine*, 2017: 1-9.

- Serra, D., Mera, P., Malandrino, M. I., Mir, J. F. & Herrero, L. (2013). Review Mitochondrial fatty acid oxidation in obesity. *Antioxidants & Redox Signaling*, 19(3): 269-84.
- Sharabiani, M. T., Vermeulen, R., Scoccianti, C., Hosnijeh, F. S., Minelli, L., Sacerdote, C., Palli, D., Krogh, V., Tumino, R., Chiodini, P., Panico, S. & Vineis, P. (2011). Immunologic profile of excessive body weight. *Biomarkers*, 16(3): 243–251.
- Sikaris, K. (2004). The clinical biochemistry of obesity. *The Clinical Biochemist Rev*iews, 25: 165–181.
- Silva, T. M. S., Camara, C. A., Lins, A. C. S., Filho, J. M. B., Silva, E. M. S., Freitas, B. M., et al. (2006). Chemical composition and free radical scavenging activity of pollen loads from stingless bee Melipona subnitida Ducke. Journal of Food Composition and Analysis, 19, 507–511.
- Silva, T. M. S., Santos, F. P., Rodrigues, A. E., Silva, E. M. S., Silva, G. S. S., Novais, J. S., et al. (2013). Phenolic compounds, melissopalynological, physicochemical analysis and antioxidant activity of jandaira (Melipona subnitida) honey. Journal of Food Composition and Analysis, 29, 10–18.
- Srinivasan, K., Patole, P., Kaul, C. & Ramarao, P. (2004). Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. *Methods and Findings in Experimental and Clinical Pharmacology*, 26(5): 327-333.
- Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C. & Ramarao, P. (2005). Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. *Pharmacological Research*, 52(4): 313-320.
- Surh, Y.J., Liem, A., Miller, J.A., Tannenbaum, S.R. (1994). 5 Sulfooxymethylfurfural as a possible ultimate mutagenic and carcinogenic metabolite of the Maillard reaction product, 5-hydroxymethylfurfural. *Carcinogenesis*, 15; 2375–2377.
- Tachakittirungrod, S., Okonogi, S. & Chowwanapoonpohn, S. (2007). Study on antioxidant activity of certain plants in Thailand: Mechanism of antioxidant action of guava leaf extract. *Food Chemistry*, 103: 381–388.
- Takahashi, M., Ikemoto, S. & Ezaki, O. (1999). Effect of the fat/carbohydrate ratio in the diet on obesity and oral glucose tolerance in C57BL/6J mice. *Journal of Nutritional Science and Vitaminology*, 45: 583–593.
- Targher, G., Chonchol, M., Zoppini, G., Abaterusso, C. & Bonora, E. (2011). Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? *Journal of Hepatology*, 54(5): 1020-1029.

- Targher, G., Day, C. P. & Bonora, E. (2010). Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *New England Journal of Medicine*, 363(14): 1341-1350.
- Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., Zoppini, G., Mantovani, W., Barbieri, E. & Byrne, C. D. (2013). Nonalcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. *PLoS One*, 8(2): e57183.
- Touyz, R. M. & Schiffrin, E. L. (1999). Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. *Hypertension*, 34(4): 976-982.
- Turner, P. V., Vaughn, E., Sunohara-Neilson, J., Ovari, J. & Leri, F. (2012). Oral gavage in rats: Animal welfare evaluation. *Journal of the American Association for Laboratory Animal Science: JAALAS*, 51(1): 25.
- Vinson, J. A., Dabbagh, Y. A., Serry, M. M., & Jang, J. (1995). Plant flavonoids, especially tea flavonols, are powerful antioxidants using an in vitro oxidation model for heart disease. *Journal of Agricultural and Food Chemistry*, 43; 2800–2802.
- Visweswara, P., Rao, K., Madhavi, M., Dhananjaya, N., Gan, S.H. (2013). "Rhinacanthus nasutus improves the levels of liver carbohydrate, protein, glycogen, and liver markers in streptozotocin-induced diabetic rats," Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 102901.
- Vit, P. (2013). Melipona favosa pot-honey from Venezuela. In P. Vit et al. (Eds.), Pothoney a legacy of stingless bees (pp. 363–373). New York: Springer.
- Warwick, Z. S. & Schiffman, S. S. (1992). Role of dietary fat in calorie intake and weight gain. *Neuroscience & Biobehavioral Reviews*, 16: 585–596.
- Woods, S. C., Seeley, R. J., Rushing, P. A., D'Alessio, D. & Tso, P. (2003). A controlled high-fat diet induces an obese syndrome in rats. *Journal of Nutrition*, 133(4): 1081-1087.
- World Health Organization. (2013). Obesity and Overweight. Fact Sheet N°311.Updated March 2013. Retrieved on 1<sup>st</sup> June 2016 at <a href="http://www.who.int/mediacentre/factsheets/fs311/en/">http://www.who.int/mediacentre/factsheets/fs311/en/</a>
- World Health Organisation, 2013. Global Database on Body Mass Index [online]. Retrieved on 30<sup>th</sup> June 2016 at <a href="http://apps.who.int/bmi/index.jsp?introPage=intro\_3.html">http://apps.who.int/bmi/index.jsp?introPage=intro\_3.html</a>

- World Health Organization. (2015). Obesity and Overweight. Fact Sheet N°311. Updated January 2015. Retrieved on 1<sup>st</sup> June 2016 at <http://www.who.int/mediacentre/factsheets/fs311/en/>
- Xu, S.-P., Mao, X.-Y., Cheng, X. & Chen, B. (2013). Ameliorating effects of casein glycomacropeptide on obesity induced by high-fat diet in male Sprague-Dawley rats. *Food and Chemical Toxicology*, 56: 1-7.
- Yeh, M. M. & Brunt, E. M. (2014). Pathological features of fatty liver disease. *Gastroenterology*, 147(4): 754-764.
- Yaghoobi N, Al-Waili N, Ghayour-Mobarhan M, Parizadehed SMR, Abaslti Z, Yaghoobi Z. (2008). Natural honey and cardiovascular risk factors; effects on blood glucose, cholesterol, triglycerole, CRP, and body weight compared with sucrose. *Science World J*;8:463-9.
- Zainol, M.I., Yusoff, K.M., Yusof, M.Y.M. (2013). Antibacterial Activity of Selected Malaysian Honey. *BMC Complementary and Alternative Medicine* 13: 129.
- Zhao, J. & Grant, S. F. (2011). Genetics of childhood obesity. *Journal of Obesity*, 2011: 1-9.